Premium
Acyclovir‐resistant herpes simplex virus infection in HIV‐infected patients: a report of three cases and a review of management
Author(s) -
Murphy M.,
Monteiro E.
Publication year - 1993
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1993.tb00060.x
Subject(s) - foscarnet , medicine , herpes simplex virus , mucocutaneous zone , virology , aciclovir , thymidine kinase , virus , valaciclovir , immunology , disease , herpesviridae , viral disease
Case reports Three cases of acyclovir‐resistant ano‐genital HSV infection. Management review Acyclovir‐resistant mucocutaneous herpes simplex virus (HSV) infections are increasingly seen in patients with advanced HIV disease. The primary mechanism of resistance is deficiency of virus specific thymidine kinase. Foscarnet, a pyrophosphate analogue, which directly inhibits HSV DNA polymerase is an effective therapeutic alternative to acyclovir, and is commonly used. Topical trifluridine recently has been useful as a non‐toxic alternative to foscarnet. Management of recusrrent episodes of acyclovir‐resistant HSV infection following successful inital or induction therapy with foscarnet requires development of a clear strategy for effective suppressive therapy.